NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/18/2023
Back to search
Official data from USPTO
WUXI XDC THE BIOCONJUGATION LEADER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
07/18/2023
Trademark type
Combined
Nice classes
40, 42
Filing date
09/18/2021
Registration date
07/18/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/18/2023
Last transaction
07/18/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2021-07-00
First use in commerce
2021-09-00
Drawing code
3
Owner type
03
Owner location
Wuxi, Jiangsu Province, KY
Examiner
HAN, DAWN L
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wordings "WUXI" over "XDC", partially inside an incomplete oval outline that intersects with another incomplete oval outline. Below these appears the wording "THE BIOCONJUGATION LEADER" in stylized font.
Holders and representatives
Holders
WuXi XDC Cayman Inc.
Representatives
Eric Lamb FROST BROWN TODD LLC
Technical classification
Nice Classes
Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of antibody-drug conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates
Class 42
Development of products for others; pharmaceutical drug development services; research and development of new products; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceuticalbiomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates
Publications
History of USPTO decisions and trademark events.
28 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/18/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/16/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
06/15/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
06/09/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/09/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/08/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/02/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/01/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
06/01/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/30/2023
IUAF
USE AMENDMENT FILED
05/05/2023
DRRR
DIVISIONAL REQUEST RECEIVED
05/05/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/05/2023
EISU
TEAS STATEMENT OF USE RECEIVED
05/05/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/08/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/13/2022
PUBO
PUBLISHED FOR OPPOSITION
09/13/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/24/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/09/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
06/28/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/28/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
06/28/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/28/2022
DOCK
ASSIGNED TO EXAMINER
06/22/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/23/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/22/2021
NWAP
NEW APPLICATION ENTERED
09/22/2021
Continuous trademark protection
Get notified about every new filing that threatens WUXI XDC THE BIOCONJUGATION LEADER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.